Evidence map›Paper›PMID 38758328›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Induction of Dormancy in Cryptococcus neoformans In Vitro: The HypNOS Protocol.

Ruchi Agrawal, Aude Sturny-Leclère, Raffael J A de Castro, Alexandre Alanio

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ruchi AgrawalDepartment of Mycology, Translational Mycology Group, Institut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Paris, France.
Aude Sturny-LeclèreDepartment of Mycology, Translational Mycology Group, Institut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Paris, France.
Raffael J A de CastroDepartment of Mycology, Translational Mycology Group, Institut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Paris, France.
Alexandre AlanioDepartment of Mycology, Translational Mycology Group, Institut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Paris, France. alexandre.alanio@pasteur.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cryptococcus neoformans is the second major cause of death in patients with HIV. During a latent infection, this pathogenic fungus survives in the host for years without causing symptoms of active disease. Upon favorable conditions, such as immunosuppression due to HIV infection, or other conditions (steroid use or organ transplantation), the yeast may reactivate and cause active cryptococcosis. Hence, dormancy is an important phase in the pathogenesis of C. neoformans. Additionally, C. neoformans also persists during antifungal treatment and causes disease recurrence, which is a major medical problem, especially in low- and middle-income countries. To survive in the host, yeast cells must react to the stresses they are exposed to and generate a cellular response that is favorable for yeast survival. A prominent strategy used by C. neoformans to combat challenging surroundings is dormancy, which may translate into a viable, but nonculturable phenotype (VBNC). This chapter describes an in vitro protocol to generate and characterize dormant Cryptococci.

Indexed as

Cryptococcus neoformansCryptococcosisHumansCryptococcus neoformansDormant cellsHypoxiaIn vitro dormancy protocolNormoxiaReactivationResuscitationViable but nonculturable phenotype

Identifiers

PMID38758328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.